These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27547001)

  • 41. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
    Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
    J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.
    Milazzo L; Magni C; Niero F; Schiavini M; Lai A; Cento V; Binda F; Antinori S; Sollima S
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1231-1234. PubMed ID: 28877086
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Frequency distribution of HCV resistance-associated variants in infected patients treated with direct-acting antivirals.
    Cabral BCA; Ramos JA; Silveira ALM; Nascimento ÉRDS; Ferreira SB; Coelho HSM; Moura-Neto RS; Villela-Nogueira CA; Hoffmann L; Silva R
    Int J Infect Dis; 2022 Feb; 115():171-177. PubMed ID: 34902582
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
    Sarrazin C
    J Hepatol; 2016 Feb; 64(2):486-504. PubMed ID: 26409317
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus.
    Sato K; Uraoka T
    World J Gastroenterol; 2018 Oct; 24(38):4304-4310. PubMed ID: 30344416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
    Tornai I
    Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct-acting antivirals for chronic hepatitis C.
    Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C.
    Elhence A; Singh A; Anand A; Kumar R; Ashraf A; Kumar S; Pradhan D; Pathak P; Vaishnav M; Rajput MS; Banyal V; Nayak B; Shalimar
    J Med Virol; 2021 Aug; 93(8):4982-4991. PubMed ID: 33783006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
    Perpiñán E; Caro-Pérez N; García-González N; Gregori J; González P; Bartres C; Soria ME; Perales C; Lens S; Mariño Z; Londoño MC; Ariza X; Koutsoudakis G; Quer J; González-Candelas F; Forns X; Pérez-Del-Pulgar S
    J Viral Hepat; 2018 Dec; 25(12):1515-1525. PubMed ID: 30141252
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Resistance Associated Mutations in HCV Patients Failing DAA Treatment.
    Di Stefano M; Faleo G; Farhan Mohamed AM; Morella S; Bruno SR; Tundo P; Fiore JR; Santantonio TA
    New Microbiol; 2021 Jan; 44(1):12-18. PubMed ID: 33453702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
    Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    J Gastroenterol; 2017 Jul; 52(7):845-854. PubMed ID: 27913920
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study.
    Safarnezhad Tameshkel F; Karbalaie Niya MH; Zamani F; Motamed N; Ajdarkosh H; Vafaeimanesh J; Khoonsari M; Sohrabi MR; Aten S; Azarkeivan A; Eslami MS; Perumal D; Maadi M; Ghanbari B; Keyvani H
    Arch Virol; 2020 Oct; 165(10):2193-2203. PubMed ID: 32638116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How much of a problem is resistance in treating hepatitis C?
    Forton DM
    Curr Opin Infect Dis; 2016 Dec; 29(6):625-631. PubMed ID: 27673712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Primer on Hepatitis C Virus Resistance to Direct-Acting Antiviral Treatment: A Practical Approach for the Treating Physician.
    Weisberg IS; Jacobson IM
    Clin Liver Dis; 2017 Nov; 21(4):659-672. PubMed ID: 28987254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
    Welch NM; Jensen DM
    Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
    Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM
    Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Direct-acting antivirals for chronic hepatitis C.
    Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD012143. PubMed ID: 28585310
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018.
    Sorbo MC; Cento V; Di Maio VC; Howe AYM; Garcia F; Perno CF; Ceccherini-Silberstein F
    Drug Resist Updat; 2018 Mar; 37():17-39. PubMed ID: 29525636
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV.
    Merli M; Rossotti R; Travi G; Ferla F; Lauterio A; Angelini Zucchetti T; Alcantarini C; Bargiacchi O; De Carlis L; Puoti M
    Transpl Infect Dis; 2019 Dec; 21(6):e13165. PubMed ID: 31487082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.